Galectin Therapeutics Secures New Funding
Galectin Therapeutics Inc. GALT, a pioneer in developing therapeutics targeting galectin-3, has made headlines by securing a significant $10 million unsecured line of credit. This funding comes from Richard E. Uihlein, who not only serves as the Chairman of the Board but is also the largest individual shareholder of the company. This new credit line aims to support the firm through to mid-2026, allowing it to advance its promising research into metabolic dysfunction-associated steatohepatitis (MASH) and related medical conditions.
Commitment to MASH Treatment
Richard E. Uihlein expressed strong confidence in Galectin's potential, particularly regarding their lead drug candidate, belapectin. He emphasized, "Belapectin has the potential to address a significant unmet medical need in MASH cirrhosis. I am fully committed to funding the Company adequately to explore the potential of its MASH cirrhosis program." Uihlein remains upbeat about ongoing developments and looks forward to upcoming data from the NAVIGATE trial.
Understanding the Credit Facility
This newly established line of credit operates at the revenue discretion of Galectin and remains open until April 30, 2026. The company is expected to pay interest rates based on the Federal Rate for short-term loans, which presently stands at 4.05% plus an additional 2%. The financial terms also stipulate that any principal and interest will be due by September 30, 2026, and are backed by convertible promissory notes with the option to convert into shares at a predetermined rate.
Future Financial Strategy
The strategic move not only provides the necessary funds for ongoing projects but also extends the maturity dates of existing convertible notes and other lines of credit from Uihlein. This extension reflects a strong financial backing as the company navigates through crucial phases of their development pipeline.
Leadership Insights
Joel Lewis, the CEO of Galectin Therapeutics, shared his appreciation for Uihlein's unwavering support, highlighting how this additional financing enables the company to minimize shareholder dilution while maximizing potential success. Lewis stated, "This new $10 million financing is projected to cover our expenditures adequately until mid-2026, which aligns perfectly with our operational timelines and goals. We are optimistic about the data we've gathered from our trials, particularly the promising Fibroscan Liver Stiffness Measure (LSM) biomarker results that were communicated through our recent updates."
About Galectin Therapeutics
Galectin Therapeutics is committed to the development of innovative solutions for patients dealing with chronic liver diseases and cancer. The company focuses on belapectin, which inhibits the galectin-3 protein associated with several severe inflammatory and fibrotic disorders. This drug has received Fast Track designation from the FDA, underscoring its potential in treating MASH cirrhosis, a significant unmet need in the medical field.
Additional Development Areas
The future development of belapectin and its applications is currently hinging on establishing partnerships that can facilitate further research and commercialization. Besides MASH cirrhosis, Galectin is also exploring opportunities in combination immunotherapy targeted at advanced head and neck cancers and other malignancies.
Contact the Company
For media inquiries or more information regarding investor relations, interested parties can contact the following representatives:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Kevin Gardner
kgardner@lifesciadvisors.com
Frequently Asked Questions
What is the purpose of the $10 million credit line secured by Galectin Therapeutics?
The credit line is intended to support ongoing research and development for treatments targeting MASH cirrhosis and portal hypertension.
Who provided the funding for Galectin Therapeutics?
The funding was provided by Richard E. Uihlein, the Chairman of the Board and largest individual shareholder of Galectin Therapeutics.
How does the credit facility operate?
The facility allows Galectin to borrow funds at its discretion until April 2026, with interest rates based on the current Federal Rate for short-term loans.
What is belapectin?
Belapectin is a galectin-3 inhibitor developed by Galectin Therapeutics, aimed at treating MASH cirrhosis and other diseases.
What are the next steps for Galectin Therapeutics?
Galectin plans to continue its clinical trials and seek partnerships to facilitate further development and potential commercialization of belapectin.
